For many people with Crohn’s disease, the most disruptive symptoms are not in the abdomen. Pain, swelling, or discharge around the back passage can be distressing, embarrassing to discuss, and easy to mistake for something minor like a haemorrhoid. Yet in Crohn’s disease this area can become a site of ongoing inflammation in its own right, requiring specific recognition and treatment.
What is perianal Crohn’s disease?
Perianal Crohn’s disease refers to inflammation and tissue damage around the anus, rather than higher up in the bowel. It can include fistulas (abnormal tunnels between the bowel and skin, or the bowel and other structures), abscesses (pus collections caused by infection), skin tags, fissures (small tears in the lining), and narrowing of the anal canal. It affects a substantial proportion of people with Crohn’s disease at some point, and can occur before, during, or independently of active bowel symptoms.
Why it matters for gut inflammation
The perianal area is lined with the same tissue type as the rest of the bowel, so it is subject to the same immune processes driving inflammation elsewhere in Crohn’s disease. When the immune system reacts abnormally to gut bacteria or lining injury, inflammatory cytokines are released, promoting tissue breakdown and abnormal healing that can allow fistulas to form between the bowel wall and skin. Constant mechanical stress from passing stool, combined with abundant local bacteria, makes this area particularly prone to chronic, hard-to-heal inflammation once a fistula develops.
Key mechanisms
Fistula formation
A fistula begins when inflammation causes a small defect in the bowel wall. As the body attempts to heal this, a tunnel can form that tracks through surrounding tissue rather than closing over. Bacteria travelling along this tunnel sustain inflammation and prevent natural healing. Fistulas are classified as simple or complex depending on their path relative to the muscles controlling continence, which affects treatment choice.
Abscess development
When a fistula tunnel blocks, or infection accumulates in surrounding tissue, pus can collect and form an abscess, typically causing worsening pain, swelling, and sometimes fever. Abscesses need draining, usually via a small surgical procedure, before other treatment can work, since untreated infection will keep driving inflammation regardless of medication.
Ongoing immune activation
Even after drainage, the underlying immune activity of Crohn’s disease can keep the fistula tract inflamed, as immune cells continue producing inflammatory signals in the tissue lining the tunnel. This is why fistulas often will not close permanently unless the wider inflammatory process is also controlled with medication.
Tissue remodelling and scarring
Long-standing inflammation can lead to fibrosis, the replacement of normal tissue with scar-like tissue. In the perianal area this can cause strictures or firm, thickened skin tags, which is one reason early, sustained control of inflammation is preferred over repeated cycles of flare and partial healing.
Symptoms such as pain or discharge do not always mean active inflammation is present; scar tissue, prior surgery, or a partially healed tract can also cause ongoing symptoms. Imaging, most commonly MRI, and specialist examination are usually needed to assess what is happening before deciding on treatment.
Treatment options
Antibiotics
Antibiotics such as metronidazole or ciprofloxacin are often used to reduce bacterial load and control infection, particularly around abscess drainage. They can improve symptoms but rarely achieve lasting fistula closure alone.
Seton placement
A seton is a soft surgical thread placed through a fistula tract to keep it open and allow continuous drainage. This prevents abscess recurrence and is often used as a bridge to further medical treatment, particularly for complex fistulas.
Biologic therapy
Anti-tumour necrosis factor (anti-TNF) medicines, which block a key inflammatory signalling molecule, are the most established medical treatment for fistulising Crohn’s disease and can achieve healing in a meaningful proportion of patients when combined with seton drainage. Other biologic classes may be considered when anti-TNF treatment is unsuitable or ineffective.
Surgical options
When medical treatment and setons fail to achieve healing, techniques such as advancement flaps, fistula tract ligation, or, in severe or recurrent disease, bowel diversion may be considered. These decisions are usually made jointly by a gastroenterologist and colorectal surgeon.
Practical takeaways
- Report new perianal pain, swelling, or discharge promptly rather than assuming it is unrelated to Crohn’s disease.
- Ask for an MRI or specialist assessment if symptoms persist, since imaging often reveals more than examination alone.
- Understand that healing usually requires a combination of surgical drainage and medication, not one or the other.
- Continue prescribed maintenance therapy even after symptoms settle, as fistulas can recur if inflammation is not controlled long term.
- Discuss any bowel or stool changes with your IBD team, as diet alone cannot resolve fistulising disease.
Conclusion
Perianal Crohn’s disease reflects the same underlying immune and inflammatory processes seen elsewhere in the bowel, but local anatomy makes fistulas and abscesses particularly persistent. Long-term control depends on combining surgical management of infection with sustained medical treatment of inflammation, rather than treating each flare in isolation. Because symptoms do not always correlate directly with active inflammation, ongoing specialist assessment is important. With consistent, coordinated care, many people achieve stable, long-term control of this aspect of their disease.
References
- Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122(4):875-880. doi:10.1053/gast.2002.32362.
- Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340(18):1398-1405. doi:10.1056/NEJM199905063401804.
- Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB. AGA technical review on perianal Crohn’s disease. Gastroenterology. 2003;125(5):1508-1530. doi:10.1016/j.gastro.2003.08.025.
- Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut. 2014;63(9):1381-1392. doi:10.1136/gutjnl-2013-306709.
- Panes J, Rimola J. Perianal fistulizing Crohn’s disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14(11):652-664. doi:10.1038/nrgastro.2017.104.
- Bouguen G, Siproudhis L, Gizard E, et al. Long-term outcome of perianal fistulizing Crohn’s disease treated with infliximab. Clin Gastroenterol Hepatol. 2013;11(8):975-981.e4. doi:10.1016/j.cgh.2012.12.042.
- Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF therapy in Crohn’s disease. Int J Mol Sci. 2018;19(8):2244. doi:10.3390/ijms19082244.
- de Groof EJ, Sahami S, Lucas C, Ponsioen CY, Bemelman WA, D’Haens GR. Treatment of perianal fistula in Crohn’s disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment. Colorectal Dis. 2016;18(7):667-675. doi:10.1111/codi.13311.
This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.